Search filters
Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 373
  • 1196
  • 568
  • 28
  • 44
  • 2
  • 1128
  • 1197
  • 5

Found 1202 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 09922 A Phase 1 Open-label Multicenter Dose-ranging Study to Investigate Safety and Tolerability Efficacy Pharmacokinetics Pharmacodynamics and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

99 years or below
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More

UPCC 46420: Phase I Open Label Multicenter Dose Escalation Study of YTB323 in Adult Patients with CLL/SLL and DLBCL

18 years - 99 years
All genders
Phase 1
Please refer to Section 2 of the full protocol (Objectives and endpoints) Please refer to Section 2 of the full protocol (Objectives and endpoints) Please refer to Section 2 of the full protocol (Objectives and endpoints)
Learn More

UPCC 26921: A Phase 1a/1b Open-label Dose-Escalation and Expansion Study of TPST-1495 as a Single Agent and in Combination with Pembrolizumab in Subjects with Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints) Please refer to Section 4 of the full protocol (Study Objectives and Endpoints)
Learn More

A Phase 1/2a Open-Label Safety Pharmacokinetic and Preliminary Efficacy Trial of Oral ATRN-119 in Patients with Advanced Solid Tumors (AR-276-01)

99 years or below
All genders
Phase 1
The study will evaluate the safety profile of escalating doses of continuous daily oral ATRN-119 and to determine the maximum tolerated dose (MTD) and recommended dose. ATRN-119 is a drug that has been developed to treat cancers by taking advantage of genetic mutations found only in the tumor and not …
Learn More

UPCC 53418: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized open label phase III trial (BELINDA)

99 years or below
All genders
We would like to rely on the WIRB as IRB of record for this study. The main purpose of this study is to find out if the investigational therapy tisagenlecleucel (i.e. CTL019, CART-19, or Kymriah®) is safe and has beneficial effects in people who have relapsed or refractory aggressive B-cell …
Learn More

Evaluating Investigational Drug AP-PA02 in Subjects with Cystic Fibrosis and Chronic Pulmonary Pseudomonas aeruginosa (Pa) Infection

18 years - 99 years
All genders
Phase 1
The purpose of this study is to evaluate an investigational drug called AP-PA02 as a possible treatment for individuals with cystic fibrosis (CF) and chronic pulmonary Pseudomonas aeruginosa (Pa) infection. There are 2 main parts to this study, Part 1 and Part 2. If you choose to take part in …
Learn More

Comparing Drug abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

18 years - 99 years
All genders
Interventional
The purpose of this study is to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking apixaban. Participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total of …
Learn More

Study Comparing the Effect of Drug Abelacimab Relative to Dalteparin on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Gastrointestinal (GI) / Genitourinary (GU) Cancer Associated VTE

18 years - 99 years
All genders
Phase 3
Interventional
This research study is being done to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking dalteparin. Your participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total …
Learn More

UPCC 18121: A Phase II Study of NirAparib Dostarlimab and Radiotherapy in Metastatic PD-L1 Negative or Immunotherapy-Refractory Triple-Negative Breast Cancer (NADiR)

99 years or below
All genders
Phase 2
Please refer to Section 4 of the full protocol (Objectives) Please refer to Section 18.4 of the full protocol (Analysis of Primary Endpoints) Please refer to Section 18.5 of the full protocol (Analysis of Secondary and Exploratory Endpoints)
Learn More

Study to Determine the Safety of Drug RNS60 in Large Vessel Occlusion Stroke Patients

18 years - 99 years
All genders
Phase 2
Interventional
Endovascular therapy is the physical removal of the clot in your brain through an artery in your groin or arm. This type of stroke is called an ischemic stroke and carries a high risk of disability or death. In this study we are trying to learn more about a new …
Learn More
481 - 490 of 1202